fda warning letter glp-1 october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Issues Warning Letters to

LG: Conceptualization, Project administration, Supervision, Visualization, Writing review & editing

RELATED: Save up to 80% on weight loss drugs Weight loss Appetite suppressants and Orlistat, Cigna (2025) Diabetes glucagon-like peptide-1 agonists prior authorization policy, Cigna (2023) Appropriate use of prescription medications for diabetes and weight loss helps to ensure patient access and safety, Cigna Diabetes Mounjaro prior authorization policy, Cigna (2023) FDA approves first medication for obstructive sleep apnea, Food and Drug Administration (2024) Cigna to offer $200 Wegovy, Zepbound weight-loss benefit, Reuters (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Cheang, J

Private insurance often excludes these drugs entirely, while Medicare is opening pathways for coverage

Quick GLP-1 Review First, let's quickly review what these medicines are

Eden explicitly advertises FSA/HSA eligibility , but its worth checking with your specific provider and plan administrator before assuming it applies